DDInter993 DDInter1652
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Isradipine {u} (Compound) resembles {v} (Compound) Amlodipine
Isradipine {u} (Compound) resembles {v} (Compound) Nimodipine
Isradipine {u} (Compound) treats {v} (Disease) hypertension
Isradipine {u} (Compound) binds {v} (Gene) CYP3A4
Isradipine {u} (Compound) upregulates {v} (Gene) KLHL21
Isradipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Isradipine {u} (Compound) downregulates {v} (Gene) MT2A
Isradipine {u} (Compound) causes {v} (Side Effect) Visual impairment
Isradipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Simvastatin
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Isradipine (Compound) resembles Amlodipine (Compound)
Isradipine (Compound) resembles Nimodipine (Compound)
Isradipine (Compound) treats hypertension (Disease)
Isradipine (Compound) binds CYP3A4 (Gene)
Isradipine (Compound) upregulates KLHL21 (Gene)
Isradipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Isradipine (Compound) downregulates MT2A (Gene)
Isradipine (Compound) causes Visual impairment (Side Effect)
Isradipine may cause a minor interaction that can limit clinical effects when taken with Simvastatin
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab